Hyloris Pharmaceuticals S.A.
Research Hyloris Pharmaceuticals S.A. (0AB6) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- Ticker0AB6
- ExchangeLSE
- CountryBelgium
- CurrencyEUR
- Financial periodFY2025
- RevenueEUR 7.21M
- Revenue growth-14.8%
- Net income-EUR 6.33M
- Free cash flow-EUR 7.62M
- Gross margin94.7%
About Hyloris Pharmaceuticals S.A.
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias;
Frequently asked questions
What does Hyloris Pharmaceuticals S.A. do?
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain;